Security
Alterity Therapeutics Ltd Ordinary Shares · PRNAF
PRNAFOTCCommon stockCurrentCIK 1131343Updated Oct 12, 2026
Name history
PRANA BIOTECHNOLOGY LTD · through Apr 8, 2019
PRNAF price & chart
Loading TradingView…
OTC:PRNAF on TradingView ↗About the company
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -12,147,828Source | -19,123,464Source | -13,806,515Source | -12,847,061Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodAUD | -9,356Source | -12,375Source | 70,651Source | 19,936Source |
| AdjustmentsForSharebasedPaymentsAUD | 979,920Source | 881,950Source | — | — |
| GeneralAndAdministrativeExpenseAUD | 5,481,399Source | 4,762,643Source | 5,056,571Source | 5,513,915Source |
| InterestPaidClassifiedAsOperatingActivitiesAUD | — | 7,217Source | 4,565Source | 2,285Source |
| InterestReceivedClassifiedAsOperatingActivitiesAUD | 446,291Source | 269,075Source | 15,798Source | 2,755Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 127,097Source | 10,370Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| AdministrativeExpenseAUD | 520,142Source | 1,028,638Source | 1,032,843Source | — |
| BasicEarningsLossPerShareAUD/shares | -0.19Source | -0.52Source | -0.57Source | -0.53Source |
| CurrentTaxExpenseIncomeAUD | 77,411Source | 58,463Source | 33,808Source | 50,072Source |
| DepreciationRightofuseAssetsAUD | 111,408Source | 112,185Source | 64,409Source | 36,366Source |
| DilutedEarningsLossPerShareAUD/shares | -0.19Source | -0.52Source | -0.57Source | -0.53Source |
| EmployeeBenefitsExpenseAUD | 2,424,781Source | 2,456,230Source | 2,720,345Source | 705,541Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 979,920Source | 881,950Source | 983,721Source | 1,506,121Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedAUD | — | — | 68,634Source | 79,309Source |
| GeneralAndAdministrativeExpenseAUD | 5,481,399Source | 4,762,643Source | 5,056,571Source | 5,513,915Source |
| IncomeTaxExpenseContinuingOperationsAUD | 68,055Source | 46,088Source | 104,459Source | 70,008Source |
| InterestExpenseAUD | 6,188Source | 7,217Source | 4,565Source | 2,285Source |
| OtherEmployeeExpenseAUD | 1,046,530Source | 515,803Source | 926,314Source | — |
| OtherIncomeAUD | 7,641,516Source | 4,019,285Source | 3,916,333Source | 5,123,525Source |
| ProfessionalFeesExpenseAUD | — | 169,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentAUD | — | — | 13,806,515Source | 12,847,061Source |
| ProfitLossBeforeTaxAUD | -12,079,773Source | -19,077,376Source | -13,702,056Source | -12,777,053Source |
| ResearchAndDevelopmentExpenseAUD | 14,404,282Source | 18,644,047Source | 13,198,583Source | 14,745,776Source |
| RevenueFromInterestAUD | 446,291Source | 268,419Source | 16,436Source | 2,504Source |
Filing attachments
ea028258001ex99-1.htm · 6-K · 2026-03-19
Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 19/3/2026 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +Security Maximum N…
Read attachment ↗ea028135201_ex99-1.htm · 6-K · 2026-03-16
Exhibit 99.1 13 March 2026 ASX Announcement UNMARKETABLE PARCEL SALE FACILITY Alterity Therapeutics Limited (ASX:ATH) (ATH or the Company) announced today that it has established an opt-out unmarketable parcel sale facility (Facility) for shareholders who hold less than $500 worth of fully paid ordinary shares in the Company (Unmarketable Parcel). The Company has established the Facility for the following reasons: To give holders of an unmarketable parcel of Shares (less than A$500) the…
Read attachment ↗ea028053501ex99-1.htm · 6-K · 2026-03-09
Exhibit 99.1 Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place …
Read attachment ↗ea027990901ex99-1.htm · 6-K · 2026-03-04
Exhibit 99.1 Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor - Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was…
Read attachment ↗ea027480801ex99-1_alterity.htm · 6-K · 2026-01-30
Exhibit 99.1 30 January 2026 Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter. ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Regulato…
Read attachment ↗ea027349001ex99-1_alterity.htm · 6-K · 2026-01-21
Exhibit 99.1 Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 January 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program i…
Read attachment ↗